Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
Autoimmune Disorders01:29

Autoimmune Disorders

2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

832
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
832

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma.

Frontiers in immunology·2026
Same author

Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.

Journal of clinical medicine·2026
Same author

Hydrophobic complementarity-determining region 3 (CDR3) sequences elucidate the cardiotoxic effects of immune checkpoint inhibitors.

Research square·2026
Same author

Tubulointerstitial inflammation driving interstitial fibrosis and tubular atrophy predicts poor renal outcome in refractory lupus nephritis.

Rheumatology (Oxford, England)·2025
Same author

Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.

Journal for immunotherapy of cancer·2025
Same journal

Harnessing Machine Learning and Electronic Health Record Data to Improve Asthma Management.

Current allergy and asthma reports·2026
Same journal

Incorporating New Guidelines into School-Based Asthma Management.

Current allergy and asthma reports·2026
Same journal

The Modern Environment and Childhood Asthma: The Role of Air Pollution and Heavy Metal Exposure.

Current allergy and asthma reports·2026
Same journal

Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.

Current allergy and asthma reports·2026
Same journal

The Role of the Indoor Exposome in Food Allergy Development.

Current allergy and asthma reports·2026
Same journal

Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial Influences.

Current allergy and asthma reports·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Checkpoint Inhibitors: Applications for Autoimmunity.

Anna S Tocheva1,2, Adam Mor3,4

  • 1Department of Medicine, NYU School of Medicine, 450 E 29th Street, Room 806, New York, NY, 10016, USA. Anna.Tocheva@nyumc.org.

Current Allergy and Asthma Reports
|September 29, 2017
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICI) fight cancer by blocking inhibitory signals, improving survival. However, they can cause toxicities, prompting research into managing these side effects and treating autoimmune diseases.

Keywords:
AutoimmunityCancerCheckpoint inhibitorsImmune checkpointsT cellsTolerance

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Experiment Videos

Last Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The immune system uses inhibitory receptors, or immune checkpoints, to regulate T cell responses.
  • Cancer cells exploit these checkpoints to evade T cell-mediated destruction.
  • Immune checkpoint inhibitors (ICI) are therapies that block these pathways, enhancing anti-tumor immunity.

Purpose of the Study:

  • To review the biology of immune checkpoints.
  • To highlight strategies for mitigating immune-related adverse events (irAEs) from ICI therapies.
  • To explore novel approaches for using immune checkpoint modulation in autoimmune disorders.

Main Methods:

  • Literature review of immune checkpoint biology.
  • Analysis of research strategies for reducing irAEs.
  • Discussion of investigational therapies for autoimmune diseases.

Main Results:

  • ICI therapies have significantly improved cancer treatment outcomes and patient survival.
  • irAEs, including inflammation and autoimmunity, are significant adverse events associated with ICI.
  • Research is ongoing to develop methods to reduce irAEs and to repurpose ICI for autoimmune conditions.

Conclusions:

  • Immune checkpoints are crucial regulators of immune responses with implications in both cancer and autoimmunity.
  • Managing irAEs is essential for the safe and effective use of ICI in oncology.
  • Targeting immune checkpoints offers potential therapeutic avenues for autoimmune diseases.